RxDoctor Payments Data

Raviteja Guddeti, MD

Interventional Cardiology · Cincinnati, OHNPI 1891101986

Payments from drug & device makers

What this record shows

This record is dominated by grants: $60,000 of the $67,964 with a category attached, or 88.3%. 17 manufacturers reported payments, led by Abbott at 35.0% of the total. Reporting peaked in 2024 at $62,506 and has fallen 93.7% since, to $3,947 in 2025.

$67,964in general payments, 2019–2025

Across 85 payments — averaging $799.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$24K
  • Medtronic$21K
  • Boston Scientific$20K
  • Edwards Lifesciences$2K
  • Teleflex LLC$368
  • Jenavalve Technology, Inc.$175
  • plus $719 from 11 others

What the payments were for

  • Consulting fees$2,4004%
  • Grants$60,00088%
  • Travel & lodging$2,9544%
  • Food & beverage$2,6104%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,964 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$118,842
Medicare patients
553
Services billed
1,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$69,535
EntrestoSacubitril/Valsartan41$36,207
FarxigaDapagliflozin Propanediol36$23,700
BrilintaTicagrelor13$16,704
JardianceEmpagliflozin19$13,540
XareltoRivaroxaban17$9,672
Metoprolol Succinate136$1,033
ClopidogrelClopidogrel Bisulfate100$842
Rosuvastatin Calcium39$621
Atorvastatin Calcium76$604
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$494
Furosemide84$322
Carvedilol40$220
Ezetimibe13$205
Potassium Chloride11$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$37$40,40349 claims
NovartisEntresto$32$36,20741 claims
Boehringer IngelheimJardiance$46$13,54019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →